Table 2.

FGFR alterations by tumor type

FGFR alteration
Indication (n)UnknownaAmplificationMutationFusionCoalterationbAny alteration
Cholangiocarcinoma (n = 11)01 (9%)3 (27%)8 (73%)011 (100%)
Glioblastoma (n = 13)04 (31%)3 (23%)13 (100%)3 (23%)13 (100%)
Urothelial (n = 30)3 (10%)4 (13%)17 (57%)11 (37%)1 (3%)27 (90%)
Non–small cell lung (n = 24)4 (17%)5 (21%)10 (42%)8 (33%)020 (83%)
Breast (n = 36)7 (19%)21 (58%)7 (19%)6 (17%)029 (81%)
Ovarian (n = 11)3 (27%)2 (18%)3 (27%)6 (55%)1 (9%)8 (73%)
Head and neck (n = 11)5 (45%)1 (9%)5 (45%)1 (9%)06 (55%)
Gastric (n = 2)1 (50%)1 (50%)0001 (50%)
Other (n = 49)29 (59%)6 (12%)9 (18%)5 (10%)020 (41%)
  • aUnknown includes subjects for whom FGFR alteration (amplification, mutation, or fusion) status was undetermined or negative and includes one subject with activated FGFR pathway (FRS2 gene amplification) but no known FGFR alteration.

  • bCoalteration includes subjects with two categories of FGFR alterations (fusion, mutation).